Management of Surgical Site Infections
Companion Consensus Statements

All statements in this document reflect the expert opinion of a multidisciplinary panel of experts. Companion consensus statements are created due to a lack of evidence on the topic under study. Prior to the creation of companion consensus statements, a systematic literature search is performed in an effort to find relevant literature. For evidence-based statements, please visit the Systematic Literature Review on the Postoperative Management of Surgical Site Infections.

Douglas Lundy, MD; Alexander McLaren, MD; Peter F Sturm, MD; Sudheer Reddy, MD; Gregory S Stacy, MD; Gwo-Chin Lee, MD; Hrayr Basmajian, MD; Thomas Fleeter, MD; Andrew Schoenfeld, MD; Andrew Schoenfeld, MD; Paul Anderson, MD; Sandra Bliss Nelson, M.D.; Kim Chillag, MD; Carter Cassidy, MD; William O. Shaffer, MD; Deborah Cummins, PhD; Jayson Murray, MA; Danielle Schulte, MS; Mukarram Mohiuddin, MPH; Mary DeMars; Kaitlyn Sevarino, MBA; Peter Shores, MPH; Anne Woznica, MLIS, AHIP

Adopted by the American Academy of Orthopaedic Surgeons Board of Directors
June 9, 2018
Disclaimer

This companion consensus statement document was developed by a multidisciplinary physician volunteer guideline development group based expert opinion. This companion consensus statement document is not intended to be a fixed protocol, as some patients may require more or less treatment or different means of diagnosis. Patient care and treatment should always be based on a clinician’s independent medical judgment, given the individual patient’s clinical circumstances.

Disclosure Requirement

In accordance with AAOS policy, all individuals whose names appear as authors or contributors to this companion consensus statement document filed a disclosure statement as part of the submission process. All panel members provided full disclosure of potential conflicts of interest prior to voting on the companion consensus statement document contained within this document.

Funding Source

This companion consensus statement document was funded exclusively by the American Academy of Orthopaedic Surgeons who received no funding from outside commercial sources to support the development of this document.

FDA Clearance

Some drugs or medical devices referenced or described in this companion consensus statement document may not have been cleared by the Food and Drug Administration (FDA) or may have been cleared for a specific use only. The FDA has stated that it is the responsibility of the physician to determine the FDA clearance status of each drug or device he or she wishes to use in clinical practice.

Copyright

All rights reserved. No part of this companion consensus statement document may be reproduced, stored in a retrieval system, or transmitted, in any form, or by any means, electronic, mechanical, photocopying, recording, or otherwise, without prior written permission from the AAOS. If you wish to request permission please contact the AAOS Evidence-Based Medicine Unit at ebm@aaos.org.

Published 2018 by the American Academy of Orthopaedic Surgeons
9400 West Higgins Rd.
Rosemont, IL 60018
First Edition
Copyright 2018 by the American Academy of Orthopaedic Surgeons
To View All AAOS Evidence-Based clinical practice guidelines and Appropriate Use Criteria in a User-Friendly Format, Please Visit the OrthoGuidelines Web-Based App at www.orthoguidelines.org or by downloading to your smartphone or tablet via the Apple and Google Play stores!
# Table of Contents

Methodology .......................................................................................................................... 5  
Companion Consensus Statements ....................................................................................... 6  
  Surgical Timing .................................................................................................................... 6  
  Risks/Harms ...................................................................................................................... 6  
  Future Research .................................................................................................................. 6  
  Timing and Implant Removal .............................................................................................. 6  
  Rationale ............................................................................................................................ 6  
  Risks/Harms ...................................................................................................................... 6  
  Future Research .................................................................................................................. 6  
  Surgical Timing and Percutaneous Drainage ....................................................................... 7  
  Risks/Harms ...................................................................................................................... 7  
  Future research .................................................................................................................. 7  
  Adjunctive Treatment .......................................................................................................... 7  
  Rationale ............................................................................................................................ 7  
  Multidisciplinary Team ........................................................................................................ 8  
  Development Group Roster ................................................................................................. 9  
  Voting Members ............................................................................................................... 9  
  Non-Voting Members ....................................................................................................... 10
Methodology
During the development of the evidence-based Management of Surgical Site Infections Systematic Literature Review (visit OrthoGuidelines to view this review) development group had the option to create companion consensus statements for any PICO questions which returned no evidence after the systematic literature review was conducted.

Companion consensus statements for this systematic literature review were created using the following steps:

1) During the final meeting, where the work group constructed recommendations based on the systematic literature review, the work group was given the opportunity to construct consensus statements for any PICO questions which returned no evidence.

2) If the work group felt that a consensus statement was warranted, they formed the language as a group and voted to approve the consensus recommendation for inclusion in this document.
Companion Consensus Statements

Surgical Timing
In the absence of reliable evidence, it is the opinion of the work group that irrigation and debridement are the cornerstones of successful management of surgical site infections and timely management is crucial, especially in the setting of orthopaedic implants.

Risks/Harms
The work group acknowledges the inherent risks of any surgery.

Future Research
Future higher quality research is necessary to explore the relationship between infection and surgical management especially regarding the optimal timing for successful outcome.

Timing and Implant Removal
In the absence of reliable evidence, it is the opinion of the work group that implants should be removed if clinically safe and feasible due to the development of biofilm creating a barrier to successful treatment.

Rationale
Regarding the role of implant removal associated with SSI, there is a paucity of research and evidence regarding the optimal implant management. The decision to retain or remove implants based on the clinical situation balancing morbity of removal with clearance of infection. While implant retention may be necessary in many cases, it is the recommendation of this committee that implants should be removed if clinically appropriate and feasible due to the development of biofilm as a barrier to successful treatment.

Risks/Harms
There are no know harms associated with implementation of this recommendation

Future Research
The literature is lacking in quality evidence addressing the risks of retained implants. The total joint literature is attempting to address this question regarding prosthesis, but there remains a void in the research regarding other orthopaedic implants. Future studies should address this knowledge gap and attempt to identify the optimal timing and method of implant hardware exchange.
Surgical Timing and Percutaneous Drainage

In the absence of reliable evidence, it is the opinion of the work group that the definitive strategy to successfully treat surgical site infections is thorough debridement.

Risks/Harms
Barring the inherent risks of any surgery, there are no known harms associated with implementation of this recommendation.

Future research
Although percutaneous drainage is an established first-line therapeutic consideration for a variety of infected fluid collections, there is a paucity of data supporting its use for fluid collections following orthopaedic surgical procedures. Future research may explore the value of percutaneous drainage of infected fluid collections in the setting of orthopaedic surgical site infection.

Adjunctive Treatment

In the absence of reliable evidence, it is the opinion of the work group that adjunctive treatment is of limited value in the management of surgical site infections.

Rationale
1. There is consensus opinion that local delivery of antibiotics could be beneficial in the management of surgical site infections.
2. In the absence of available evidence, there is no benefit in the use of topically applied antibiotics.
3. The workgroup believes that there is lack of quality evidence for or against the use of negative pressure wound therapy in the treatment of surgical site infections.
4. The consensus of the workgroup is that there is no benefit in the use of antibiotics or antiseptics in irrigation solution in the management of these infections.
5. There is consensus opinion that appropriate soft-tissue coverage of open wounds is advantageous in the treatment of surgical site infections.
6. The workgroup believes that there is no quality literature that supports the use of adjuvant hyperbaric oxygen therapy in the treatment of patients with surgical site infections.
7. Further research is required to develop high-quality evidence to support the use of these adjuvant treatments.
Multidisciplinary Team

In the absence of reliable evidence, it is the opinion of the work group that patients with surgical site infections are optimally managed by a multidisciplinary team with expertise in the management of musculoskeletal infections. In addition to individual patient care management, multidisciplinary orthopaedic infection teams may strive to improve diagnostic capabilities, streamline care, create and maintain care pathways, coordinate discharge planning efforts, facilitate quality improvement efforts and improve patient education.

Rationale

The composition of a multidisciplinary team will depend upon local resources; optimally the team should include orthopaedic surgeons and infectious disease experts. Others whose input would be valuable in some settings: include plastic surgeons and other wound care experts, pharmacists, nursing personnel, pathologists, microbiologists, radiologists, discharge planners, and home health providers. Infectious disease experts aid in the interpretation of diagnostic tests, selection of optimal antimicrobials based on microbial and host factors, and facilitation of safe antimicrobial administration oversight. Surgeons with soft tissue coverage expertise may be helpful. Physical therapists provide modalities to mitigate lost range of motion in associated joints, degreased muscle strength, general deconditioning and to control edema. Hospitalist medicine specialists and primary care providers are often necessary for optimization of patients’ overall health. Laboratory personnel can assure proper acquisition, handling, and testing of specimens. Early planning for discharge is coordinated by discharge planning staff, pharmacy technicians, and home health care services.
# Development Group Roster

## Voting Members

1. **Douglas Lundy, MD**—Co-Chair  
   *Orthopaedic Trauma Association*

2. **Alexander McLaren, MD**—Co-Chair  
   *Musculoskeletal Infection Society*

3. **Peter F. Sturm, MD**  
   *Pediatric Orthopaedic Society of North America*

4. **Sudheer Reddy, MD**  
   *American Academy of Orthopaedic Surgeons*

5. **Gregory S. Stacy, MD**  
   *American College of Radiology*

6. **Gwo-Chin Lee, MD**  
   *The Knee Society*

7. **Hrayr Basmajian, MD**  
   *American Academy of Orthopaedic Surgeons*

8. **Thomas Fleeter, MD**  
   *American Academy of Orthopaedic Surgeons*

9. **Paul Anderson, MD**  
   *American Academy of Orthopaedic Surgeons*

10. **Sandra B. Nelson, MD**  
    *Infectious Diseases Society of America*

11. **Joseph Hsu, MD**  
    *Orthopaedic Trauma Association*

12. **Kim Chillag, MD**  
    *American Academy of Orthopaedic Surgeons*
Non-Voting Members

**Oversight Chair**
Carter Cassidy, MD
Member of the AAOS Committee on Evidence-Based Quality and Value

**AAOS Staff**

**William O. Shaffer, MD**
Medical Director

**Deborah S. Cummins, PhD**
Director of Research, Quality & Scientific Affairs

**Jayson N. Murray, MA**
Senior Manager, Quality and Value Unit

**Mary DeMars**
Administrative Assistant, Quality and Value Unit

**Mukarram Mohiuddin, MPH**
Lead Research Analyst, Quality and Value Unit

**Danielle Schulte, MS**
Research Analyst, Quality and Value Unit

**Peter Shores, MPH**
Statistician, Quality and Value Unit

**Kaitlyn Sevarino, MBA**
Manager, Quality and Value Dissemination
AAOS Clinical Practice Guidelines Section Leader
Gregory Brown, MD, PhD

AAOS Committee on Evidence-Based Quality and Value Chair
Kevin Shea, MD

AAOS Council on Research and Quality Chair
Robert H. Quinn, MD

ADDITIONAL CONTRIBUTING MEMBERS
The following participants contributed to the development of the preliminary recommendations during the introductory meeting, but did not participate in the final meeting where the evidence was reviewed and the final recommendations were developed:

Douglas Osmon, MD
Musculoskeletal Infection Society

Eric Hume, MD
American Academy of Orthopaedic Surgeons

Robert Brophy, MD
American Orthopaedic Society of Sports Medicine